BackBioNexus Gene Lab Overview

BioNexus Gene Lab Accounts Payable

Track BioNexus Gene Lab's accounts payable ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$0.00
↓ 100.00% YoYΔ $-1.37M vs prior year quarter

Peer trimmed avg / median

Loading

BioNexus Gene Lab Accounts Payable History

Loading

BioNexus Gene Lab vs. peers: Accounts Payable Comparison

Loading

BioNexus Gene Lab Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

BioNexus Gene Lab (BGLC) FAQ

As of the most recent data (June 2026), BGLC shows a accounts payable of $0. That compares with $1.4M in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BGLC's accounts payable is now $0 (was $1.4M) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether BioNexus Gene Lab is outperforming or lagging.

Tracking BGLC's accounts payable over time shows whether BioNexus Gene Lab is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $1.4M in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has BioNexus Gene Lab's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $0) with ownership activity and broader fundamentals.